SG10202005298RA - Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor - Google Patents

Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Info

Publication number
SG10202005298RA
SG10202005298RA SG10202005298RA SG10202005298RA SG10202005298RA SG 10202005298R A SG10202005298R A SG 10202005298RA SG 10202005298R A SG10202005298R A SG 10202005298RA SG 10202005298R A SG10202005298R A SG 10202005298RA SG 10202005298R A SG10202005298R A SG 10202005298RA
Authority
SG
Singapore
Prior art keywords
fucose
deoxy
fluoro
combination
cancer treatment
Prior art date
Application number
SG10202005298RA
Inventor
Shyra Gardai
Che-Leung Law
Peter Senter
Nicole Okeley
Jessica Field
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG10202005298RA publication Critical patent/SG10202005298RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG10202005298RA 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor SG10202005298RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263228P 2015-12-04 2015-12-04
US201662308583P 2016-03-15 2016-03-15
US201662321857P 2016-04-13 2016-04-13

Publications (1)

Publication Number Publication Date
SG10202005298RA true SG10202005298RA (en) 2020-07-29

Family

ID=58797961

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202005298RA SG10202005298RA (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201804263PA SG11201804263PA (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201804263PA SG11201804263PA (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Country Status (13)

Country Link
US (1) US20180353524A1 (en)
EP (1) EP3383404A4 (en)
JP (1) JP6906520B2 (en)
KR (1) KR20180086233A (en)
CN (1) CN108289903B (en)
AU (1) AU2016362993A1 (en)
BR (1) BR112018011261A2 (en)
CA (1) CA3005997A1 (en)
EA (1) EA201891340A1 (en)
IL (1) IL259479B (en)
MX (1) MX2018006674A (en)
SG (2) SG10202005298RA (en)
WO (1) WO2017096274A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356671B (en) 2010-08-05 2018-06-08 Seattle Genetics Inc Methods of inhibition of protein fucosylation in vivo using fucose analogs.
TW202246349A (en) 2016-10-11 2022-12-01 美商艾吉納斯公司 Anti-lag-3 antibodies and methods of use thereof
MA50865A (en) * 2017-06-07 2020-04-15 Seattle Genetics Inc REDUCED SURFACE FUCOSYLATION T LYMPHOCYTES AND METHODS FOR THE PRODUCTION AND USE OF THE SAME
WO2019075449A1 (en) * 2017-10-13 2019-04-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune surveillance in melanoma
US11401339B2 (en) 2018-08-23 2022-08-02 Seagen Inc. Anti-TIGIT antibodies
WO2020132096A1 (en) * 2018-12-19 2020-06-25 Seattle Genetics, Inc. Controlled fucosylation of antibodies
WO2021034774A1 (en) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN111973749B (en) * 2020-09-07 2023-03-21 威海人生药业集团股份有限公司 Pharmaceutical composition for anti-tumor immunotherapy
WO2022221766A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN113274502B (en) * 2021-05-05 2023-01-03 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Compositions for specific type three-negative breast cancer immunotherapy
WO2022236017A1 (en) * 2021-05-06 2022-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. L-fucose and anti-androgen receptor therapy for treatment of cancer
CN113413465B (en) * 2021-06-15 2022-06-03 北京大学 Application of fucosylation inhibitor in resisting inflammation caused by cancer
CN115466297B (en) * 2022-08-25 2023-07-07 青岛农业大学 Application of L-fucose and animal feed

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356671B (en) 2010-08-05 2018-06-08 Seattle Genetics Inc Methods of inhibition of protein fucosylation in vivo using fucose analogs.
US20150273033A1 (en) * 2013-11-05 2015-10-01 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer

Also Published As

Publication number Publication date
IL259479B (en) 2022-03-01
EA201891340A1 (en) 2018-11-30
MX2018006674A (en) 2018-11-09
EP3383404A1 (en) 2018-10-10
SG11201804263PA (en) 2018-06-28
CA3005997A1 (en) 2017-06-08
JP2019501145A (en) 2019-01-17
CN108289903A (en) 2018-07-17
AU2016362993A1 (en) 2018-07-12
CN108289903B (en) 2021-08-03
KR20180086233A (en) 2018-07-30
BR112018011261A2 (en) 2018-11-21
EP3383404A4 (en) 2019-07-31
JP6906520B2 (en) 2021-07-21
WO2017096274A1 (en) 2017-06-08
US20180353524A1 (en) 2018-12-13
IL259479A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
IL259479B (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
IL249476A0 (en) Combination therapy with glutaminase inhibitors
EP3360283C0 (en) Distributed transactions with token-associated execution
IL251630A0 (en) Combination therapy for use in cancer therapy
LT3371165T (en) A btk inhibitor for use in treating cancer
HUE038541T2 (en) Cancer treatments
IL256467A (en) A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
IL251905A0 (en) Apilimod for use in the treatment of renal cancer
GB201511382D0 (en) Novel compounds and their use in therapy
GB201517416D0 (en) Task-execution in a DBMS using stored procedures
GB201521304D0 (en) Tokenisation in cardholder - not - present transactions
IL262143A (en) Improvements in cancer treatment
SI3463436T1 (en) A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
PL3157548T3 (en) Therapy using a factor xii inhibitor in a neurotraumatic disorder
GB201523035D0 (en) In terferometry
IL246628A0 (en) A benzonitrile derivative and its use in renal cancer
GB201518961D0 (en) Improvements in drawings boards
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201411111D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201508117D0 (en) A cancer therapy
GB201514777D0 (en) Cancer Treatments
GB201504119D0 (en) Improvements in swim nappies
GB201405143D0 (en) Programming in computing
GB201409978D0 (en) Novel compounds and their use in therapy